Future studies, including patients with Lewy body disease and Parkinson's disease with biomarker evidence of pathology, are needed to characterise the pericyte dysfunction and CSF PDGFRβ metabolism in synucleinopathies. The gene discussed is PDGFRB; the disease is synucleinopathy.